Original SAMS post Nov 4. Replaced with de novo Claude version Nov 9.

 

Wednesday, November 4, 2026

CMS PULLS ALGORITHMIC LAB SERVICES OFF THE CLFS POLICY SYSTEM: Final Rules CY2027

Find the inspection copy OPPS rule here:

https://www.federalregister.gov/public-inspection/2026-22739/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment

Find the inspection copy PFS rule here:

https://www.federalregister.gov/public-inspection/2026-22743/medicare-and-medicaid-programs-calendar-year-2027-payment-policies-under-the-physician-fee-schedule

###

AI CORNER

###

EXECUTIVE SUMMARY

• CMS has finalized a major change in Medicare payment policy for algorithm-only laboratory tests, effective January 2027. 
• CPT codes previously paid under the Clinical Laboratory Fee Schedule (CLFS) (n=14) will instead be treated as other diagnostic tests.  That means, they'll be paid under rules for the Hospital Outpatient Prospective Payment System (OPPS) or the Physician Fee Schedule (PFS). 
• 
  
• Initial payment rates will approximate existing CLFS rates, but conventional Medicare coinsurance will apply.  
• Laboratory-specific rules, including the 14-day date-of-service rule, will no longer apply. 
• CMS corrected several code classifications following public comments but retained its fundamental policy. 
• Important questions remain about future pricing, packaging, and regulation.

###

CMS Final Rules for 2027: Software-Based Laboratory Tests Move Off the CLFS

   

1. OPPS Final Rule: SaMS Analyses Performed on Laboratory Tests

See CMS-1850-FC, Section X.B.2, esp. Table 85

CMS has largely finalized its proposed policy, with important corrections to the affected CPT codes.

CMS maintains that a stand-alone algorithmic analysis of previously generated laboratory data is not a clinical diagnostic laboratory test (CDLT), even if it has traditionally been coded and paid as one.  That was then.  This is now.

Instead, CMS considers them as other diagnostic test under Social Security Act §1861(s)(3).

This represents a substantial break from the historical CLFS treatment of these services, including the established AMA CPT coding process and CMS crosswalk/gapfill procedures. CMS rejected laboratory-industry arguments that laboratory-derived data interpretation remains intrinsically part of the laboratory service.

Payment and the 14 affected codes

CMS finalized 14 codes, compared with 10 in the original proposal. For CY 2027, they receive new technology APC assignments with status indicator O1, allowing separate payment without multiple-procedure discounting.

The final APC assignments are:

14 CPT codes	OPPS New technology APC	Standard payment
0510U	1506	$450.50
0512U, 0513U, 0414U, 0418U, 0220U, 0376U, 1106T, 1107T, 1097T, 1063T, 1064T	1509	$750.50
81417	1505	$350.50
81427	1522	$2,250.50

Source: OPPS final rule, Table 85, pp. 21–23 of the supplied laboratory excerpt. The amounts are standard APC payment rates, before applicable OPPS adjustments.

CMS bases the assignments principally on CY 2026 CLFS payment rates. Because new technology APCs have fixed payment bands, the new payments approximate ($250, $350, $450, etc).

Corrections to the July proposal

CMS made several important adjustments following public comment that highlighted errors and problems.

• Removed 0511U and 81416: CMS accepted that these services include wet-laboratory work and should remain on the CLFS. Deleted code 0208U was also removed.

• Retained 0414U and 0220U: CMS rejected objections that these services may entail wet-laboratory components, concluding that their descriptors primarily identify algorithmic analyses.

• Added 81417 and 81427: These codes for re-evaluation of previously obtained exome and genome sequences had been omitted from the proposal.

• Raised 1063T and 1064T: CMS changed the bladder cancer algorithm codes from proposed APC 1542, paying $350.50, to APC 1509, paying $750.50, based on comparability to other services.

The treatment of codes involving staining or slide digitization when performed remains an interesting definitional issue. CMS insists its policy concerns stand-alone computational services, while retaining several codes whose descriptors contemplate preparatory laboratory activity.

 

Important consequences beyond price

Beneficiary cost-sharing. These services will enter ordinary OPPS payment rules, including 20% beneficiary coinsurance, rather than remaining under the generally no-copayment CLFS.

The 14-day rule. CMS explicitly confirms that SaMS analyses performed on laboratory tests are no longer governed by the laboratory date-of-service regulation at 42 CFR 414.510. This affects a longstanding issue in separately billing molecular and genomic testing following hospital encounters.  For example, it could be payable the day after inpatient discharge, when a DNA test would still be bundled 14 days. 

An inpatient biopsy on July 1 has DNA extraction on July 3, sequencing on July 5, one type of report signed out on July 7.  The data is used for an algorithm and reported on July 9.  The DOS of the    DNA report is July 1 (date of biopsy) but the DOS of the algorithm test is July 9 (date of performance, no special rule.)  The July report has DOS July 1 and is bundled to DRG, the July 9 AI test is not bundled since it is "not a lab test."

CLIA and FDA. CMS emphasizes that the payment change does not itself revise CLIA requirements. It also distinguishes these laboratory-derived SaMS from the FDA-regulated SaMS devices addressed in the preceding OPPS section: FDA marketing authorization is not currently required for the laboratory-derived category.  

Packaging. For 2027, status indicator for SAMS, O1 provides separate payment, and new technology APC services are protected from comprehensive APC packaging. That is reassuring in the immediate term. Longer-term treatment is less certain, especially given the OPPS tradition of packaging most ordinary laboratory services, apart from molecular pathology and certain other exceptions. See: "APPENDIX - Packaging."

Pricing new tests. CMS finalizes assignment of future new laboratory SaMS codes to new technology APCs but does not establish a comparably detailed initial valuation process. With these servicesnow being outside the CLFS, the usual summer crosswalk/gapfill process is no longer the entry point for establishing their prices. CMS acknowledges the need for further development of its APC assignment methods.

Test design.  There may be some tests that are advantaged by having no included wet lab, other tests where one arbitrarily wants to include some wet lab component to "force" the CLFS/ADLT pathway.

Coding.  Remember for a couple years CPT has taken the position that PLA codes MUST  contain new wet lab biomarkers, so CMS algorithm codes won't generally be under PLA. That is, CMS rule for new wetlab = PLA  rule for new wetlab.   In 2026, CPT has made several Cat III codes for H&E SW LDT.  (And watch in 2027 for CMAA codes, TBD.)

The Words of the Code.  Note that CMS makes its decisions based on "words of the code," even when reference to the actual named test would be quick and clarifying.

Proprietary Codes.  PLA codes can only be open use if FDA approved.  Cat III codes always can be open use (if too specific...), potentially friendlier to RUO software deployed at multiple locations and "codifiable" as long as 1 lab gets a Cat III.  This sounds like inside baseball but could be pretty important in some LDT scenarios.

2. PFS Final Rule: SaMS Laboratory Analyses

See CMS-1848-F, Section (61), esp. Table A-D8

The most significant PFS change from the proposal is CMS's decision to reject contractor pricing.

The proposed rule would have placed the identified algorithmic services under Medicare Administrative Contractor pricing, potentially generating geographic variability and uncertainty.

Commenters objected, pointing out that the underlying services have no obvious jurisdiction-specific cost differences and that the proposal would unnecessarily disrupt nationally established prices.

CMS agreed. The final rule establishes national PFS pricing for the same 14 laboratory SaMS codes, with procedure status indicator A (active).

The conversion from OPPS dollars into RVUs

CMS uses the OPPS new technology APC payment as the starting point. It then calculates the practice expense RVU component by dividing the OPPS payment by the CY 2027 PFS conversion factor.

 

In broad terms, a service with an OPPS payment of $750.50 is translated into RVUs using the approximately $34 conversion factor, then translated back into dollars when paid under the PFS.

This preserves the approximate payment level while integrating the code into the PFS structure. However, ordinary PFS geographic adjustments and future conversion-factor changes mean that actual payments need not exactly match the OPPS amount in every location or future year.

 

Other consequences

Like the OPPS rule, the PFS final rule confirms that these services are other diagnostic tests rather than CLFS laboratory services. Consequently, conventional PFS beneficiary cost-sharing will apply, and CMS confirms that the CLFS date-of-service rule will not.

CAP, in its roles supporting CLIA and lab quality, has certainly viewed algorithms and  AI and machine learning as part of its modern domain.   Will CMS and CLIA central office weigh in on that/

The final rule responds to concerns about whether independent laboratories can bill directly for these services primarily by stating that the codes will be actively priced under the PFS. To my surprise, CMS acts dumb and does not fully work through the operational implications for laboratories performing computational analyses independently of physician offices or hospital outpatient departments.

CAP has long suggested CMS put genetic tests under RVUs (dating back to 2013).  Algorithm lab codse will be priced via RVUs, so CAP may revive its proposal to match.

The same important question about new test valuation remains. For the first 14 codes, CMS had existing CLFS prices to anchor the OPPS rates, which in turn anchor the PFS RVUs. That historical reference will not necessarily exist for future codes. The final rule does not fully resolve how new services will obtain an initial valuation (the one that is crosswalked into NT APCs) outside the established CLFS process.

3. OPPS General SaMS Final Rule

See CMS-1850-FC, Section X.B.1, preceding the OPPS laboratory discussion

This broader policy is important because the laboratory changes are an extension of CMS's effort to establish a consistent Medicare payment category for algorithm-based diagnostic software.

From SaaS to SaMS

CMS finalizes the terminology change from Software as a Service (SaaS) to Software as a Medical Service (SaMS).

The category encompasses algorithm-driven services supporting medical decision-making, including analysis of imaging, cardiovascular information, and other previously acquired clinical data.

The original proposal identified 36 SaMS codes, including services already receiving separate payment under clinical APCs or new technology APCs.

Standardization through new technology APCs

CMS generally finalizes reassignment of separately paid SaMS services from clinical APCs to new technology APCs, while maintaining payment levels reasonably close to CY 2026 amounts.

CMS also adopts status indicator O1, with the same payment specifications as status indicator S. Thus, O1 services are separately payable and are not subject to multiple-procedure discounting.

However, the general SaMS policy does not make every algorithm-based service separately payable. CMS preserves existing conditional packaging for certain Q1 services and complete packaging for certain N services. For example, it declines requests to change the conditional packaging status of retinal imaging codes 92227 and 92228.

These distinctions are important when considering how CMS may eventually structure payment for laboratory-derived SaMS. 

FDA authorization, coverage, and specific code decisions

For the general SaMS services in Section X.B.1, CMS requires FDA marketing authorization for Medicare payment. This contrasts with the laboratory-derived SaMS category in Section X.B.2, where such authorization is not currently required.

CMS also emphasizes that SaMS classification and APC assignment are payment decisions, not guarantees of Medicare coverage or medical necessity.

Several individual code decisions illustrate the interim approach. CMS added Cardiosense code 1036T at $150.50, burn-analysis code 0972T at $250.50, and EEG-analysis code 1041T at $150.50, resisting some requests for substantially higher initial payment. In other instances, it retained the proposed APC despite industry arguments that existing resource costs justified an increase.

Longer-term SaMS policy remains unsettled

The general SaMS discussion is explicit that 2027 represents an interim step, not a permanent payment framework. CMS received comments advocating dedicated cost centers and revenue codes, better reporting of software licensing and implementation costs, and payment approaches incorporating clinical value.

CMS indicates that it will consider these suggestions in developing possible CY 2028 proposals.

This creates a central uncertainty for both imaging-based and laboratory-based SaMS: whether the eventual permanent policy will retain individual separate payments, introduce more systematic cost-based valuation, adopt different payment categories, or increase packaging.

Overall significance

The immediate effect of the 2027 rules is principally a change in Medicare payment classification, rather than a wholesale repricing of existing tests.

But the longer-term implications are potentially much larger. By removing stand-alone computational analyses from the CLFS, CMS moves these services away from laboratory-specific pricing and billing protections and into the OPPS/PFS structures, with their coinsurance, budget-neutrality, geographic-adjustment, and packaging mechanisms.

The unresolved challenge is particularly striking for new tests: CMS has established where they will be paid, but has not yet fully established how their initial payment amounts will be determined. That may become one of the most consequential questions for algorithm-driven genomics and molecular diagnostics over the next several rulemaking cycles.

APPENDIX 1 - BUNDLING/PACKAGING

The distinction is that S is a general-purpose separate-payment indicator, while O1 is a new, software-specific separate-payment indicator. Both provide separate APC payment under OPPS, but O1 identifies Software as a Medical Service (SaMS) and, under CMS's interim 2027 policy, generally uses New Technology APCs rather than conventional clinical APCs.

A Hidden Advantage for Algorithmic Services Under OPPS. Moving standalone algorithms off the Clinical Laboratory Fee Schedule (CLFS) could improve their hospital outpatient reimbursement. Most conventional laboratory tests carry status indicator Q4, meaning payment is generally bundled into an accompanying clinic visit, emergency department visit, or other outpatient service. By contrast, CMS has established a new status indicator, O1, for Software as a Medical Service (SaMS), providing separate payment through an APC. O1 resembles the existing S indicator, which also provides separate payment without multiple-procedure discounting, as exemplified by autonomous retinal diagnostic code 92229. The difference is that O1 specifically identifies software-based medical services and assigns them to New Technology APCs under an interim payment policy, rather than treating them as conventional clinical procedures. Although CMS may revise the methodology, the immediate implication is significant: moving an algorithm out of the laboratory category can replace routine Q4 packaging with a pathway to separate hospital outpatient payment.

APPENDIX 2 - -A HARDWARE / WETWARE SAMS PARADOX 

###

One clear paradox.  CMS states that algorithmic lab services with no wetlab component are not CLFS, but if the algorithmic lab service DOES contain a real-world (wet lab0 component, it isn't SAMS and stays on PFS.    In sharp contrast, SAMS in general can contain both real-world and algorithmic components, like 92229 (digital camera, lens, focus, lighting, etc PLUS AI algorithm to render retinal diagnosis w/o physician work. OPPS table 84. [BQ]

### [AI]

The SaMS Paradox: When Physical Work Counts—and When It Doesn't

There is a striking inconsistency in CMS's reasoning, although the agency has left itself a possible legal distinction.

For laboratory-derived SaMS, CMS draws a fairly sharp line: if a CPT code describes only secondary computational analysis of previously generated laboratory data, it is no longer a clinical laboratory test and leaves the CLFS. If the code encompasses actual specimen analysis, as with 0511U or 81416, CMS agrees it is an integrated laboratory service and leaves it on the CLFS.

Yet SaMS generally is not restricted to software-only services.

Consider CPT 92229, which CMS retains as SaMS in OPPS Table 84. The service encompasses retinal imaging and autonomous algorithmic interpretation. The camera, optics, illumination, focusing, and image acquisition are integral to obtaining the diagnostic result. It is hardly a service delivered by an algorithm alone. Nevertheless, CMS assigns the entire service to SaMS, with status indicator O1 and new technology APC 1502.

There are even more explicit examples. CPT 1105T includes actual acquisition of EEG and ECG signals, followed by algorithmic analysis. CMS newly designates it SaMS. Similarly, CPT 0972T includes multispectral imaging, system setup, and image acquisition, yet also qualifies as SaMS.

Thus, CMS is not consistently applying a principle that SaMS must consist exclusively of computational work.

Can the distinction be defended?

CMS could argue that it is answering two different questions.

In the laboratory context, the question is whether a service qualifies under the statutory clinical diagnostic laboratory test benefit category, with its particular payment and regulatory requirements. CMS treats secondary analysis of previously obtained data as an other diagnostic test.  But if wetlab is done, that overrides SAMS and "pulls" the test into CLFS.

In the broader SaMS context, the question is whether algorithm-driven diagnostic technology belongs in the new SaMS payment category, even when the service also includes the physical acquisition of the underlying data.  (See retinal camera 92229 and its digital AI report, below).  

That is a plausible legal distinction. But it is not a consistent functional definition of SaMS.

Indeed, the distinction becomes particularly awkward for pathology-based software that includes preparation or digitization of glass slides. Codes 1063T and 1064T explicitly contemplate H&E staining and slide digitization when performed, yet CMS includes them among the 14 laboratory-derived SaMS services leaving the CLFS.  So CMS is treating these as if the wetlab doesn't exist, and presumably doesn't value it.  But CPT doesn't want you to bill the wetlab service (e.g. IHC) if the  CPT code absorbs it, "if performed."   So you're blocked from billing for example IHC x 7, if performed.

So the presence of physical work is disqualifying in some laboratory codes, permissible in other laboratory codes, and entirely compatible with SaMS designation in imaging and other diagnostic specialties.

The most charitable interpretation is that CMS is trying to preserve existing integrated laboratory tests while carving out independently identifiable computational services. However, the resulting boundary depends heavily on the individual CPT descriptor, its historical coding conventions, and CMS's interpretation of optional physical components.

That is a precarious foundation for an increasingly consequential payment classification.  CMS does not discuss that wetlab boots you out of SaMS in lab and lab data world, but physical events (like the 92229 physical camera) is compatible with treatment as a clinical software service.

And the paradox has a series of practical reimbursement consequences. Whether physical activity is included in a single CPT code, or separated into two codes describing acquisition and subsequent analysis, may determine whether a service remains on the CLFS, receives conventional coinsurance, escapes the laboratory date-of-service rule, and ultimately becomes subject to OPPS packaging.

The larger lesson may be that CMS has created a payment category called Software as a Medical Service without yet establishing any consistent principle for how much non-software activity that service can contain. The agency acknowledges that its 2027 policy is interim. The unresolved definitional problem may prove considerably harder to resolve than the initial payment assignments.

###

The paradox is not merely semantic. CMS applies opposite reasoning to the presence of physical diagnostic work, depending on whether the service originated in the laboratory or elsewhere.

Consider the contrast:

- CPT 92229 (retinal imaging): Physical image acquisition, involving a camera, optics, illumination, and positioning, is combined with an algorithmic diagnostic interpretation. CMS classifies the entire service as SaMS.

- CPT 0511U (tumor drug-response testing): Physical laboratory activity is combined with computational prediction. CMS concludes that the physical laboratory component prevents the service from being classified as SaMS, retaining it on the CLFS.

Both are integrated diagnostic services involving physical procedures and algorithms. Yet in one case the physical component is compatible with SaMS classification; in the other it is grounds for exclusion from a lab SaMS.

CMS can invoke the distinct statutory treatment of laboratory tests to explain the administrative result. But that does not resolve the conceptual inconsistency in what constitutes Software as a Medical Service.

The paradox is that physical diagnostic work does not disqualify a service from being SaMS—unless that physical work happens to be laboratory work.

And that makes SaMS less a coherent technological category than a classification shaped by the historical boundaries of Medicare payment systems.

There is no need to force a reconciliation. The inconsistency is itself the important finding about these tricky final rules.

###

83861 tears

 ophthalmologists microfluidic analysis of tears, 83861.

6.2M out of 7M.

PAMA

22.48 to 22.03

Cologuard Quotations about COGS of Cologuard Plus

 Direct quotations from Chat GPT including prompt.

##

   Let's pivot back to Cologuard coding.   Cologuard Plus 0464U was priced by CMS in CY2024, inititially proposed at parity to Cologuard Original about $520 and   later raised by cMS to 81327x3 or nearly $600.   

However, I seem to recall statements by Exact sciences that the operating costs or COGS or Cologuard Plus would be less - COGS is less - than had been the case for Cologuard Original.   Your assignment is to use agentic reserach and search the internet for quotations or statements where Exact sciencee (or, if demarcated as such, analysts) imply or statte that COGS goes down for Cologuard Plus.    

###

Yes—your recollection is correct, and the evidence is explicit and repeated. 

Exact Sciences management described the next-generation Cologuard test as costing at least 5% less per test in 2023, reiterated lower COGS during the 2024 pricing process, and stated in May 2025 that Cologuard Plus cost about 5%–6% less to run than original Cologuard. These are company statements, not merely analyst inferences. The Motley Fool

• There is also a useful rediscovery: you covered this yourself on November 6, 2024, in “Exact Sciences—Earnings Call a Tutorial in Crosswalk and ADLT pricing.” Your post specifically highlighted the lower cost of goods for Cologuard Plus. discoveriesinhealthpolicy.com

The strongest passages follow. Quotations are short exact excerpts; the surrounding explanations are paraphrases.

1. June 21, 2023: Company-hosted Investor Day transcript—explicit COGS reduction and an operational explanation

Jeff Elliott, CFO, discussing the next-generation product then called Cologuard 2, said:

“we expect at least a 5% reduction in cost of goods per test”

In the preceding answer, Jake Orville explained that one of the two laboratory processing lines described during the investor tour would go away with Cologuard 2, connecting that simplification to approximately 5% lower costs.

Elliott placed the product improvement within a broader ambition to reduce Cologuard cost per test from approximately $125 to $100 or less. The entire $125-to-$100 reduction should not be attributed to Plus alone: he also discussed continued improvements and laboratory operating leverage. s22.q4cdn.com

Exact Sciences Investor Day transcript, PDF pages 29–30

This is particularly useful evidence because the transcript is hosted with the company’s investor materials and predates the CMS pricing proceedings.

2. August 1, 2023: Q2 earnings call—direct comparison with original Cologuard

Jeff Elliott, CFO and COO, answering a question about Cologuard 2 cost of goods:

“the cost per test of Cologuard 2 will be at least 5% lower than what it is today for Cologuard 1.”

He attributed the reduction to the development of more accurate markers, automation, and efficiencies incorporated into the new test. This is the clearest early statement comparing the two generations directly. The Motley Fool

Q2 2023 earnings-call transcript

3. March 14, 2024: Company presentation—fewer markers and better laboratory throughput

Slide 6 of Exact Sciences’ BLUE-C presentation states:

“Cologuard Plus delivers performance and cost advantages”

The slide depicts a reduction from 11 markers to five and identifies improved laboratory throughput. It does not quantify COGS savings, but it provides company-authored support for the operational explanation behind the earnings-call statements. s22.q4cdn.com

Exact Sciences BLUE-C presentation, slide 6

4. November 5, 2024: Q3 earnings call—higher selling price and lower COGS discussed together

Aaron Bloomer, CFO, described an expected gross-margin benefit in 2025:

“with the launch of Cologuard Plus, which will give us added ASP as well as lower cost of goods.”

This statement occurred during the same fall in which CMS was finalizing the new test’s payment determination. It explicitly identifies two separate favorable effects: higher average selling price and lower production costs. The Motley Fool

Q3 2024 earnings-call transcript

5. May 1, 2025: Q1 earnings call—approximately 5%–6% lower cost to run Plus

Aaron Bloomer, CFO, answering Barclays analyst Luke Sergott’s question about gross margins:

“the actual cost to run the test is lower by about 5% or 6% than it is for Cologuard.”

The immediately preceding wording identifies Cologuard Plus as the test being compared with original Cologuard. Bloomer also acknowledged potential transition costs from sorting specimens and running the two product lines concurrently. He expected the pricing benefit to more than offset those potential headwinds. marketbeat.com

Q1 2025 transcript, approximately 44:25 into the call

This is the strongest later confirmation: the company was still describing lower unit operating costs as the product entered commercial use.

Secondary reporting also noticed the combination of higher requested payment and lower costs.

• July 26, 2024—Investing.com: Its report on the Medicare advisory-panel discussion juxtaposed Exact’s requested 25% price increase with the company’s expectation of 5% lower COGS. This is secondary financial reporting, not a CMS finding or an original analyst research note. The page discloses AI assistance and editorial review. investing.com
• November 26, 2024—Investing.com, reporting on Leerink Partners’ outlook: The article described the favorable final Medicare pricing decision alongside 5% lower COGS for Plus, attributing that cost expectation to company management. Again, this is a media account of the analyst outlook, rather than the underlying Leerink note. investing.com

For your purposes, the direct company statements above are stronger evidence than either secondary article.

The defensible conclusion is that Exact repeatedly represented Plus as a less expensive test to produce, despite seeking and obtaining higher reimbursement. The evidence concerns per-test COGS or the cost of running the assay. It does not mean total corporate spending fell, nor does it independently establish an audited, fully allocated cost for each product.

A concise formulation you can use is:

Exact Sciences repeatedly told investors that Cologuard Plus would have lower per-test costs than original Cologuard. Management projected at least a 5% reduction in 2023, reiterated lower COGS alongside anticipated higher selling prices in November 2024, and described a 5%–6% lower cost to run the test in May 2025. The Motley Fool

One small correction to the coding premise: CMS’s official CY2025 mapping is 0464U → 81327 × 3 + 82274—81327, rather than 83127 [i fixed in my prompt above], and including the fecal hemoglobin component. CMS documented that crosswalk in its December 13, 2024 transmittal. cms.gov

##

private link at

https://chatgpt.com/c/6ad998cf-d4a4-83e8-9333-9c882d6c5a47

Pulling FDA Docket Comments per Chat GPT

 Yes—you can automate both the downloading and the screening, without manually opening 129 PDFs. And I found a particularly useful shortcut for this exact docket.

Someone has already collected and analyzed much of it. Innolitics published a “Running Census” of FDA-2026-N-7874. Its author reports retrieving 107 comments and 92 PDF/Word attachments through the Regulations.gov API, then extracting their text. The version I could read describes a September 21 snapshot, so it should not be treated as complete coverage of the 129 you see now. Nevertheless, it provides an immediate starting point for finding substantive comments. Innolitics

For your own complete collection, here are the practical options:

What you want	How to accomplish it
Download everything without clicking each comment	Use the official API to enumerate comments and retrieve each comment’s attachment links; a script downloads the files automatically.
Find comments of three or more pages	Have software count pages in every downloaded PDF and create a sortable index. No manual opening required.
Identify organizations hidden behind personal names	Extract the attachment text and examine letterheads, opening paragraphs, and signatures. Preserve the portal’s submitter name in a separate column.
Search reliably for “California”	Search the locally extracted text of both comment bodies and attachments, using OCR for scanned files.
Prioritize substantive submissions	Combine page count, word count, organizational affiliation, and the presence of concrete recommendations.

The official Regulations.gov API documentation supports retrieving comment details with attachments and explains API-key registration. This is an automated sequence of downloads, rather than necessarily a single “download docket ZIP” button. GSA Open Technology

Your “California” experience is a reason not to trust a zero-result search as proof of absence. One plausible explanation is that the searchable listing contains “John Smith” and “See attached,” while “University of California Health” appears inside the PDF. Attachment indexing, scanning, or posting delays could also matter. I haven’t verified which explanation applies to that particular submission, so I would not categorically claim that the portal never searches attachments.

There is also an Export route, with an important distinction: exporting a spreadsheet of comment records is not the same as downloading their attachments. George Washington University’s Regulatory Studies Center documents an export-plus-script workflow and provides public code for downloading comments and converting attachments to text. Its instructions refer to an older interface/API, so I would use it as a model rather than assume it runs unchanged today. I could not verify the current export-button placement through my web access. GitHub

For your research, the most useful result would be a comment index with:

• Organization identified from the actual letter.
• Portal submitter name and comment ID.
• PDF page count and extracted word count.
• A one-sentence description of the argument.
• Direct attachment link.
• Flags for “three-plus pages,” “needs OCR,” and “duplicate.”

I would use three-plus pages as a priority flag, not an exclusion rule: a two-page institutional letter can contain an important position, while a long attachment may mostly reproduce background material. The automated approach makes both visible.

#### HOW DO IT

####

Absolutely. My previous answer skipped over the difficult part: “use the API” is an instruction for a programmer, not a usable set of directions.

And you’re right that we need the comments submitted near October 19. The September snapshot is insufficient for that purpose. I haven’t verified the submission-date breakdown, so I can’t confirm whether those late comments constitute the majority.

I found an easier place to start: Regulations.gov has a “Bulk Data Download” feature that does not require programming. GSA documents it specifically as a way to download information without technical expertise. It emails you a spreadsheet file. GSA

Here is the plain-English procedure:

1. Open Regulations.gov.
2. Scroll to the bottom of the page and look for “Bulk Data Download.” Alternatively, look on the homepage for “Create Custom Download.”
3. Choose the option to download by Docket ID.
4. Paste this identifier: FDA-2026-N-7874
5. Follow the prompts to request the download and provide your email address.
6. Look for an email from no-reply@regulations.gov. Download the CSV file using its link. “CSV” simply means a spreadsheet that Excel can open.
7. Upload that file here. You don’t need to clean it up first.

Those are GSA’s published directions; the announcement is archived, so the precise button wording or placement may have changed. If your screen differs, send me a screenshot. GSA

Important: that first download is the catalog of comments—not a folder containing all the PDFs. Once you upload it, I can inspect whether it includes the attachment download links. That determines the simplest way to collect the actual files in a batch.

For comparison, here is what the API approach means in ordinary language:

Term	What it means
API	A way for a program to ask Regulations.gov for information automatically.
API key	A registration code that identifies the program’s requests.
Download script	A small program that asks for the comment list, finds each attachment, and downloads the files for you.

The API route requires registering for a key, then running a prepared program. Getting a key alone does not produce the PDFs. The official API supplies comment details and attachment information; the program handles the repeated downloading. GSA Open Technology

For you, I suggest starting with the seven steps above. The immediate goal is to get the current docket’s spreadsheet here. Then we can work toward a folder of PDFs and an index showing organization, page count, and subject—without your opening each submission yourself.

Four Transcripts and a Funeral: AI Reads Invitae's Last Year

 (We asked AI to read the last 4 OPKO investor calls prior to the divestiture of Bioreference to Labcorp.  Here, we show the result when we gave the same task but for Invitae's last 4 investor calls.)

 ###

Ernst & Young gave the 2022 financials an unqualified audit opinion without a going-concern paragraph. The formal “substantial doubt” conclusion first appears in management’s Q3 2023 10-Q; Invitae then highlighted it explicitly on the November earnings call. SEC

Here is the first-pass case study.

Invitae: The Last Four Calls

A business case in growth, capital structure, genomic medicine, and the narrowing path from turnaround to Chapter 11

Invitae Corporation, February 2023–February 2024

Executive Summary

Invitae entered 2023 describing a dramatic corporate restructuring as largely accomplished. Management had cut costs, sold noncore assets, refinanced near-term debt, and projected a cash runway through the end of 2024. Across its next two quarterly calls, the company repeatedly emphasized improving gross margins, sharply reduced cash burn, a “strong cash position,” and approximately $250 million of additional secured borrowing capacity. By August, Invitae was actually lowering its projected 2023 cash burn despite reducing revenue guidance. Three months later, however, the language changed abruptly: the Q3 10-Q stated that substantial doubt existed about Invitae’s ability to continue as a going concern, while a board special committee began evaluating capital raises, debt restructuring and asset sales. Ninety-seven days after that final earnings call, Invitae filed Chapter 11. Labcorp ultimately acquired the operating business for $239 million. The case illustrates a critical distinction: operational improvement can be real while the capital structure has already become untenable.

I. Background: Building the Genetics Platform

Invitae was founded around a compelling and unusually ambitious proposition: genetic information should become inexpensive enough, comprehensive enough, and sufficiently integrated into ordinary medicine that genomic testing would move from a specialist service into mainstream healthcare.

The strategy required scale. Invitae drove testing prices downward, expanded its menu, accumulated genetic data, built relationships with biopharmaceutical companies, and pursued acquisitions intended to create a comprehensive genetics platform.

For a period, capital markets rewarded the ambition.

The acquisition program eventually extended well beyond conventional hereditary-disease germline testing. Invitae purchased pharmacogenomics capabilities, reproductive-health businesses, digital tools and oncology technologies. The largest transaction was the 2020 acquisition of ArcherDX. Invitae agreed to pay 30 million shares plus $325 million cash upfront, with as many as another 27 million shares contingent on milestones. At announcement, the transaction was valued at approximately $1.4 billion. Management described the combination as creating a global leader spanning inherited cancer risk, tumor profiling, liquid biopsy and cancer monitoring.

The strategy produced breadth, but it also produced complexity, spending and substantial capital requirements. By 2022 the environment had changed. Growth-oriented biotechnology and diagnostics companies could no longer assume inexpensive capital would remain indefinitely available.

In July 2022, Invitae changed direction dramatically. Founder-CEO Sean George was succeeded by COO Ken Knight. The company announced a strategic realignment that included eliminating more than 1,000 positions, consolidating facilities, abandoning noncore products and reducing its international presence from more than 100 countries and territories to fewer than a dozen. Management estimated approximately $326 million in annualized savings once the restructuring was fully implemented.

The bankruptcy court record would later characterize the period even more starkly. Invitae experienced turnover among four CFOs over approximately two years, alongside other C-suite changes. In the company's own first-day bankruptcy declaration, that turnover was described as having delayed the company's response to its challenges and impeded development of a cohesive go-forward strategy.

Thus the four final earnings calls did not begin with a healthy growth company suddenly entering distress. They began midway through an attempted rescue.

II. The Four Calls

There was no Q4 2023 earnings call. Invitae's Q3 2023 call on November 8, 2023 became its final quarterly investor call. The natural four-call sequence therefore begins with Q4 2022 and ends with Q3 2023.

Quarter	Call date	Public financial narrative
Q4 2022	February 28, 2023	Debt problem substantially addressed; runway through 2024
Q1 2023	May 9, 2023	Strong execution; burn falling faster than expected
Q2 2023	August 8, 2023	Revenue softens, but burn forecast improves further
Q3 2023	November 8, 2023	“Substantial doubt”; special committee; capital structure options
Chapter 11	February 13, 2024	Court-supervised sale process

February 28, 2023 — Q4 2022: “A More Stable Financing Footing”

This was the optimistic opening chapter.

The 2022 restructuring appeared to be working. Invitae reported approximately $122 million of fourth-quarter revenue. Ongoing quarterly cash burn had fallen to about $77 million, compared with $196 million a year earlier. Management projected more than $500 million in 2023 revenue and full-year ongoing cash burn of $250–275 million — less than half the 2022 level.

But the principal strategic message concerned the balance sheet.

Invitae had arranged a $336 million transaction led by Deerfield that exchanged most of the convertible debt due in 2024 for new secured notes extending into 2028. It also repaid a $135 million term loan. CFO Roxi Wen said the transactions would reduce total debt by more than $165 million and shrink the 2024 maturity from approximately $485 million to only $14 million.

Management estimated a pro forma cash balance of approximately $450 million.

The conclusion was emphatic: Invitae expected its cash runway to extend through the end of 2024 and said it retained approximately $245 million of additional secured debt capacity. Wen characterized the refinancing as a “fundamental change” benefiting Invitae's capital structure and financial health.

CEO Ken Knight's operating message was similarly constructive. Invitae had “stabilized” its portfolio. Profitable growth was now the foundation of the 2023 business plan, while investment could continue in new growth opportunities such as personalized cancer monitoring.

Case interpretation: February 2023 did not sound like the beginning of a bankruptcy countdown. It sounded like the end of a financial crisis. Management presented both halves of the turnaround — operations and financing — as materially improved.

There was, however, a less comforting fact beneath the refinancing. The new 2028 notes were secured by a first-priority lien on substantially all of Invitae's and its subsidiaries' assets, including intellectual property. The company had bought time, but the capital structure was becoming increasingly creditor-centered.

III. May 9, 2023 — Q1: “Same Mission, New Path”

The first-quarter call reinforced the turnaround narrative.

Revenue was $117.4 million. Non-GAAP gross margin reached 47.9%, compared with 36.6% for 2022. Ongoing cash burn was approximately $51 million, about 70% below the prior-year Q1. Invitae reported approximately $389 million of cash, restricted cash and marketable securities after repaying the term loan.

Management again referred to its “strong cash position” and emphasized nearly $250 million of available secured debt capacity. Revenue guidance remained above $500 million for 2023. Cash-burn guidance remained $250–275 million, with management saying results were tracking toward the favorable end of the range.

Knight ended the prepared remarks with language that now reads strikingly in retrospect: the near-term debt had been “substantially” addressed, the balance sheet had improved, and additional secured capacity remained available.

His summary was: “same mission, new path.”

The contemporaneous 10-Q supported the public presentation, although with important caveats. Invitae stated that its cash, investments and operating receipts should be sufficient for at least the following twelve months. It simultaneously acknowledged that it expected to require additional financing before profitability and that such financing might not be available on acceptable terms.

Case interpretation: Q1 may be the point at which a reader looking only at quarterly operating trends could most easily conclude that Invitae had escaped its crisis. Cash burn was collapsing; margin was improving; immediate debt maturities had been pushed out.

The unresolved issue was not yet whether the underlying laboratory business could improve. It clearly was improving.

The question was whether it could improve fast enough to outrun the balance sheet.

IV. August 8, 2023 — Q2: Better Cash Burn, Worse Revenue

The second-quarter call contains perhaps the most instructive contradiction in the entire case.

Knight opened by saying Invitae was continuing its “steady march toward becoming a profitable business.” Non-GAAP gross margin reached 49.8%, its eighth consecutive quarter of improvement. Ongoing cash burn was approximately $53 million, 64% lower than the comparable quarter in 2022.

Cash and investments stood at approximately $336 million, down from $389 million at the end of Q1. Again, management described the balance as a “strong cash position.” Again, it said approximately $250 million of additional secured debt capacity remained available.

There were genuine operating problems. Revenue was approximately $121 million, down from $137 million reported in the prior-year period, although management emphasized that discontinued operations distorted the comparison. On a pro forma basis, growth was only about 1%.

Hereditary-cancer reimbursement had weakened. Oncology fee-for-service revenue was soft. Invitae abandoned pharmacogenomic testing because the reimbursement path and required investment no longer fit management's desired time horizon.

Consequently, management reduced 2023 revenue guidance from more than $500 million to $480–500 million.

Ordinarily, a revenue-guidance cut at a cash-burning company might imply deterioration in liquidity expectations.

Invitae reported the opposite.

Management improved its cash-burn guidance from $250–275 million to $220–245 million, saying the company was ahead of plan.

Knight concluded that one year after the strategic realignment, Invitae had better visibility into the portfolio and had created “doable paths for profitable growth tomorrow.”

The Q2 10-Q still concluded that Invitae's available liquidity would cover at least the next twelve months, although it explicitly stated that external capital would be needed beyond that period and that such funding had not been secured.

Case interpretation: August 2023 is the most deceptive moment if operating metrics are viewed independently of financing conditions.

Gross margin was improving. Cash burn was substantially lower. Burn guidance was getting better.

Yet the company's dependence on future financing had not disappeared.

Invitae had solved a rate-of-burn problem more successfully than it had solved a capital-structure problem.

V. November 8, 2023 — Q3: The Language Changes

Three months later, the central premise of the story changed.

Operationally, Invitae could still report substantial progress. Q3 revenue was $121.2 million, approximately 4% higher on management's pro forma basis. Non-GAAP gross margin reached 52.4%, the ninth consecutive quarter of expansion. Management reaffirmed its $480–500 million revenue forecast and $220–245 million ongoing cash-burn guidance.

If the case consisted only of revenue, margin and operating-efficiency slides, the turnaround still looked alive.

Then Knight said:

“Today you will see going concern language in our 10-Q.”

The accompanying filing was unequivocal. Because of losses, projected cash needs and existing liquidity, “substantial doubt exists about the Company's ability to continue as a going concern.” Management said continued operation depended on successfully reducing costs and improving liquidity. Alternatives included new debt or equity, asset sales, business and R&D refocusing, and further reductions in spending. If adequate funding could not be obtained, the filing specifically identified liquidation or bankruptcy proceedings among the possible outcomes.

The board had formed a special committee focused on the capital structure. Management told investors it was exploring raising capital, addressing debt, selling assets and further cost reductions.

New CFO Ana Schrank reported approximately $265 million of cash, restricted cash and marketable securities. Quarterly ongoing cash burn had increased to approximately $64 million, partly because of interest and other one-time payments. She emphasized that Invitae still had sufficient liquidity to operate normally while management worked with stakeholders on a path forward.

The company continued discussing 2024.

Management talked about future margin expansion, product mix and continued growth. Knight said Invitae remained “pretty darn confident” that gross-margin improvement could continue into the future.

Case interpretation: Q3 contains two narratives simultaneously.

The operating business was demonstrably becoming more efficient.

The corporation financing that business was running out of strategic freedom.

That distinction is the heart of the Invitae case.

SIDEBAR: The Going-Concern Threshold

The accounting progression is worth isolating because hindsight can otherwise make bankruptcy appear more obviously imminent than it actually looked in contemporaneous filings.

At December 31, 2022, Invitae stated that available cash and investments should cover at least twelve months. Ernst & Young issued an unqualified audit opinion on the 2022 financial statements and did not add a going-concern explanatory paragraph.

At March 31, 2023, management again stated that existing liquidity should satisfy expected cash needs for at least twelve months, while acknowledging that more capital would ultimately be required.

At June 30, 2023, management again made essentially the same twelve-month liquidity determination.

At September 30, 2023, the conclusion flipped. Management determined that losses, future cash requirements and available liquidity raised substantial doubt about Invitae's ability to continue as a going concern.

So the important event was not a long-standing auditor qualification that investors ignored. It was an abrupt transition in management's own required ASC 205-40 assessment between the Q2 and Q3 filings.

That makes the November call more consequential, not less.

The company crossed a formal accounting threshold at almost exactly the same moment that its public capital-allocation discussion shifted from financing a turnaround toward restructuring the enterprise itself.

VI. Ninety-Seven Days Later

On February 13, 2024, 97 days after the Q3 call, Invitae and several subsidiaries filed voluntary Chapter 11 petitions in New Jersey.

The filing was not designed simply to reorganize debt and return the same public corporation to shareholders. Invitae entered bankruptcy with a transaction-support agreement backed by holders representing approximately 78% of its secured notes and pursued a court-supervised sale of the operating business.

The contemplated plan provided that existing equity interests would be cancelled without distribution.

The debt refinancing celebrated one year earlier now assumed a different significance. The secured notes issued in 2023 had claims against substantially all of Invitae's assets. In bankruptcy, their holders were among the parties supporting the sale process.

This does not make the February 2023 refinancing irrational. Without it, Invitae faced approximately $485 million of 2024 maturities and might have failed sooner. The transaction bought time.

But it bought time, not solvency.

VII. Labcorp: $239 Million for the Operating Platform

The bankruptcy auction eventually produced a familiar buyer: Labcorp.

Labcorp won the auction for selected Invitae assets and agreed to pay $239 million in cash, plus assumption of specified liabilities and other noncash consideration. The bankruptcy court approved the transaction in May 2024.

Labcorp expected the acquired operation to generate approximately $275–300 million of annual revenue, principally in specialty genetics such as oncology and rare disease.

That relationship between revenue and purchase price is striking.

Invitae had once assembled a broad genetics platform through years of investment and acquisitions. ArcherDX alone had carried an announced transaction value of approximately $1.4 billion.

The surviving operating genetics platform was ultimately sold out of bankruptcy to Labcorp for $239 million.

Those numbers should not be treated as a clean investment-return calculation. The businesses, assets, liabilities, market conditions and time periods are different. But as a corporate-strategy picture, the contrast is extraordinary.

VIII. What Actually Failed?

The easiest explanation is that Invitae's business failed.

That is too simple.

During the terminal four calls, several elements of the operating business were moving in the right direction. Gross margins rose for nine consecutive quarters. Cash burn fell dramatically from its 2021–2022 levels. Certain hereditary disease and women's-health businesses continued growing. The company accumulated one of the industry's largest clinical genetics datasets and retained genuine technological capabilities.

Labcorp's willingness to pay $239 million and continue the business confirms that the operating assets were not worthless.

A more useful diagnosis is that Invitae's capital structure failed before the operating turnaround could reach self-sustainability.

The company had built its platform during an era when equity and debt capital were unusually available. It made acquisitions, expanded globally and tolerated very large operating losses in pursuit of scale.

When capital markets changed, management attempted to reverse that model rapidly: fewer countries, fewer employees, fewer products, higher-quality revenue, better reimbursement, lower costs.

The restructuring achieved impressive operating savings.

But a company burning $50–60 million per quarter while carrying substantial secured and convertible debt does not merely need improving margins. It needs either positive cash flow soon enough or continuing access to outside capital.

By Q3 2023, the latter assumption had broken.

The 10-Q explicitly referred to difficult debt markets. The board was no longer merely optimizing operations. It was evaluating the capital structure itself.

IX. The Most Interesting Feature of the Four Calls

The most revealing sequence is therefore not:

Optimism → deterioration → bankruptcy.

It is:

Operational deterioration → restructuring → genuine operational improvement → financing failure → bankruptcy.

That is a considerably more interesting business case.

In February 2023 management could accurately say that cash burn had improved dramatically and near-term maturities had been pushed out.

In May, it could accurately say that gross margins were improving and burn was ahead of plan.

In August, it could accurately say that cash-burn guidance had improved further.

And in November, it could accurately report its best gross margin in years while simultaneously concluding that substantial doubt existed about the company's ability to continue.

All four statements can be true.

That is precisely what makes the case valuable.

X. BioReference and Invitae: An Unexpected Labcorp Parallel

The coincidence with BioReference is worth noting.

Labcorp ultimately acquired both businesses, but through radically different paths.

BioReference spent its terminal year inside OPKO being rationalized, narrowed and publicly described as approaching sustainable profitability. OPKO then negotiated a strategic sale at a substantial price.

Invitae spent its terminal year being rationalized, narrowed and publicly described as moving toward profitable growth. But its capital structure deprived management of the luxury of waiting for that thesis to mature. The sale occurred only after Chapter 11, under court supervision, for $239 million.

In both cases, scale mattered.

A testing platform that struggled to create adequate returns as an independent or noncore enterprise could be more valuable inside Labcorp, where laboratory infrastructure, contracting, logistics, payer relationships and commercial reach already existed.

The difference was bargaining power.

OPKO could sell BioReference from a position in which it still had strategic alternatives.

Invitae entered the sale process because its alternatives had largely disappeared.

XI. Conclusion: The Difference Between Runway and Escape Velocity

The phrase that echoes through Invitae's final year is cash runway.

Management improved it. It refinanced debt. It cut spending. It sold businesses. It reduced employment. It expanded margins.

But runway is not the same thing as escape velocity.

Invitae entered 2023 believing that a dramatically lower burn rate, improved reimbursement and renewed growth could give the operating business sufficient time to become financially self-sustaining.

For much of the year, the reported operating metrics supported that thesis.

What changed was the availability of the bridge between the present and that future.

By November, outside capital could no longer be treated as an ordinary planning assumption. The Q3 going-concern disclosure effectively acknowledged that operational improvement alone might not arrive quickly enough.

Ninety-seven days later, Invitae entered Chapter 11.

The core genetics platform survived.

The public corporation did not.

And Labcorp, rather than Invitae's shareholders, became the owner positioned to test whether the long-promised economics of scale in clinical genetics could finally be realized.

The part I find most interesting is Q2 → Q3. In August, Invitae still said it had a “strong cash position,” roughly $250 million of additional secured debt capacity, and actually improved its burn guidance. In November, the secured borrowing capacity essentially disappears from the rhetorical foreground and is replaced by going concern, stakeholders, special committee, debt, asset sales. That is the inflection point I would visually emphasize if we turn this into the companion PDF to the BioReference report. The Motley Fool

Opko Bioreference rewrittten as case study; HTML cut paste version

 

BioReference: The Terminal Year

A business case in corporate strategy, laboratory economics, and the evolution of management's public narrative

OPKO Health and BioReference, October 2025–October 2026

Executive Summary

In October 2026, OPKO Health announced an agreement to sell substantially all remaining BioReference laboratory operations to Labcorp for $722 million, plus up to $150 million contingent on future 4Kscore revenue. The transaction marked the effective end of BioReference as a major independent competitor in American clinical laboratory testing. Yet OPKO's four preceding quarterly earnings calls told a different, though not necessarily contradictory, story. Following two earlier divestitures, management repeatedly characterized BioReference as a streamlined, regionally focused enterprise approaching sustainable profitability, supported by cost reductions, selective growth, and the proprietary 4Kscore prostate cancer test. By mid-2026, however, the promised turnaround remained incomplete. This case reconstructs the public narrative quarter by quarter, distinguishing management's operational forecasts from the strategic logic ultimately revealed by the sale. It examines how an apparently viable turnaround became an exit strategy—and what the episode illustrates about scale, specialized diagnostics, and capital allocation in a consolidating industry.

I. Industry Context: From the Big Three to the Big Two

For decades, the American clinical laboratory industry has combined two quite different business models. One is the large-scale processing of routine diagnostic tests: chemistry, hematology, microbiology, urinalysis, and common immunoassays. The other is specialized testing, where proprietary technology, clinical validation, reimbursement, and physician adoption can be more important than raw specimen volume.

The routine laboratory business is fundamentally a scale enterprise. Major fixed costs include laboratory facilities, instrumentation, information systems, specimen logistics, quality assurance, and regulatory compliance. Large national laboratories can spread these costs across enormous specimen volumes, negotiate purchasing arrangements, maintain extensive courier networks, and offer physicians comprehensive test menus.

Two companies have long dominated the national independent laboratory market: Quest Diagnostics and Labcorp. BioReference Laboratories, founded in 1981 and built into a major regional and national competitor under longtime executive Marc Grodman, emerged as an important third force. Its distinctive assets included a substantial New York–New Jersey franchise, women's health testing, oncology diagnostics, and a growing menu of specialized services.

Calling these the industry's Big Three is useful shorthand, though not a literal description of three equally sized companies. Quest and Labcorp were considerably larger than BioReference, while hospital-based laboratories and other independent and specialty laboratories also held substantial market shares. Nevertheless, BioReference was large enough to represent a meaningful independent competitive alternative.

OPKO Health acquired BioReference in 2015 in an all-stock transaction valued at approximately $1.47 billion. The acquisition combined an established clinical laboratory enterprise with OPKO's ambitions in pharmaceutical development and proprietary diagnostics, especially its 4Kscore prostate cancer blood test.

The subsequent decade illustrated the difficulty of integrating those ambitions. BioReference experienced a dramatic but temporary revenue surge during COVID-19 testing. As pandemic demand disappeared, the company faced declining revenue, substantial infrastructure costs, and the competitive realities of a business in which national scale increasingly mattered.

A laboratory dismantled in stages

The October 2026 announcement was not the beginning of BioReference's breakup. It was the third major transaction in a sequence:

Date	Transaction	Consideration
September 2024	Sale to Labcorp of selected clinical, reproductive, and women's health testing operations outside NY/NJ	$237.5 million
September 2025	Sale of oncology diagnostics and related testing assets to Labcorp	Up to $225 million
October 2026	Agreement to sell remaining core clinical laboratory operations, corrections business, and 4Kscore to Labcorp	$722 million plus up to $150 million contingent

The first two sales had already reduced BioReference's national footprint and eliminated several laboratory facilities. OPKO's 2025 annual report described a workforce reduction from approximately 3,300 employees before restructuring to 1,373 by December 31, 2025.

OPKO Health, Inc. (OPK)

The final transaction was announced October 15, 2026, under an agreement signed October 14. It includes clinical and women's health testing, urology, corrections testing, more than 80 patient service centers, and 4Kscore. Labcorp estimates approximately $250 million in revenue from the acquired business in its first year after closing. Regulatory approvals and other closing conditions remain outstanding.

SEC

+1

Thus, BioReference's transition from a national independent competitor to a collection of businesses inside Labcorp was nearly complete. The historic Big Three were becoming, in practical terms, the Big Two.

But throughout the last year, OPKO's public descriptions of its remaining laboratory business focused less on exit than on renewal.

II. The Terminal Year: Four Earnings Calls

The four quarterly calls, beginning in October 2025, provide a remarkably consistent sequence of public statements. Management described the same basic strategy throughout: reduce costs, concentrate geographically, increase profitable testing, and expand 4Kscore. What changed was the evidence that the strategy could deliver profitability on the promised timetable.

October 29, 2025 — Q3 2025: A New Beginning

The October call followed the September sale of BioReference's oncology operations to Labcorp. Management presented the transaction as a decisive restructuring that would enable the remaining company to operate more efficiently.

Chief Executive Officer Phillip Frost and President Elias Zerhouni emphasized that BioReference was no longer trying to sustain a sprawling national laboratory infrastructure. Its remaining business would concentrate on three complementary activities: regional clinical laboratory testing in New York and New Jersey, national correctional health testing, and the proprietary 4Kscore test.

The remaining operations had identifiable advantages. BioReference retained established relationships with physicians and institutional customers in its core region. Correctional health provided a national customer base with specialized logistical requirements. And 4Kscore offered a differentiated test whose economics might be more attractive than routine clinical testing.

Management reported approximately 5.3% year-over-year growth in testing volume for the retained operations, excluding divested assets. The company's public materials also highlighted approximately 20% growth in 4Kscore testing volume.

The message was forward-looking and constructive. Divestitures were presented as a way to eliminate complexity and release the profitability embedded in the remaining business. The 2025 FDA labeling change removing the requirement for digital rectal examination information in the 4Kscore algorithm was particularly important. It created the possibility of expanding adoption beyond specialist urologists into primary care, where most initial PSA testing originates.

Case interpretation: October 2025 established the central turnaround thesis. BioReference was not described as a declining asset awaiting disposal, but as a newly focused business with a clearer commercial strategy and potentially better margins.

February 26, 2026 — Q4 2025: The Turnaround Takes Shape

The February earnings call offered the strongest articulation of BioReference's prospects.

OPKO reported that the retained business represented approximately $300 million in annual revenue. Fourth-quarter testing volume had increased modestly, and cost reductions were beginning to show results.

The workforce reduction was particularly striking. Management reported that BioReference had approximately 1,400 full-time employees, down roughly 29% year over year. The remaining enterprise had been reorganized around a smaller geographic footprint and a more selective test menu.

Frost described the company as positioned for sustained profitable growth in 2026. Zerhouni emphasized the importance of correctional health, higher-margin specialty testing, and expansion of 4Kscore. CFO Adam Logal reinforced expectations for additional efficiency gains.

The financial commitment was explicit: management expected BioReference to achieve positive operating income and cash flow during 2026.

This was a significant claim. A laboratory business generating approximately $300 million in annual revenue could be a useful contributor to OPKO if it became consistently profitable. Equally important, successful execution would demonstrate that the earlier divestitures had created a sustainable business rather than merely a smaller one.

The company's annual report, filed the same day, reinforced the strategy. It identified increasing 4Kscore sales, gaining share in New York and New Jersey, and achieving sustainable profitability as BioReference's near-term objectives.

The Motley Fool

+1

Case interpretation: The February call was the high point of management's turnaround narrative. BioReference had a coherent operating model, identifiable growth initiatives, and a forecast for positive operating income and cash flow. The remaining question was execution.

April 28, 2026 — Q1 2026: Encouraging Operating Evidence

The April call appeared to validate portions of the turnaround thesis.

Management reported that average daily accessions had increased more than 3% sequentially. Correctional health and other institutional accounts were important contributors, while higher-margin services continued to gain traction.

Margins had improved compared with the fourth quarter of 2025. Management attributed the improvement to both increased volume and operating efficiencies. Headcount was reduced by another approximately 4%.

The 4Kscore opportunity remained central. Management again discussed the significance of the FDA labeling change and the possibility of broader use among primary care physicians. The commercial argument was straightforward: a blood test used to refine prostate biopsy decisions might achieve materially greater volume if ordering no longer depended as heavily on urology practices.

Yet the profitability forecast was becoming more specific—and potentially more demanding. Management expressed confidence that BioReference could reach breakeven around the middle of 2026.

That formulation mattered. Rather than reporting that the laboratory had already crossed into sustained profitability, management was identifying a near-term milestone that had not yet been achieved.

There was also an important difference between improving margins and generating adequate returns on invested capital. A company can show better quarterly operating trends while remaining structurally disadvantaged relative to larger competitors.

Still, the April presentation gave investors reasonable grounds to believe the restructuring was progressing. The company was reporting real operating improvements, not merely projecting hypothetical savings.

Investing.com

Case interpretation: April 2026 provided the strongest evidence that management's operational program was working. But it also made the approaching profitability milestone a concrete test of the turnaround.

July 27, 2026 — Q2 2026: The Turnaround Remains Unfinished

The July call, approximately eleven weeks before the sale announcement, was the most revealing of the four.

Management continued to describe BioReference as a focused clinical laboratory business with a valuable national specialty franchise. Zerhouni again emphasized the 4Kscore test as an important growth driver, with the potential to generate substantial revenue and profitability as payer coverage and physician adoption expanded.

The financial results, however, showed that the path to profitability remained difficult.

Diagnostics revenue for the quarter was $74.5 million, including $6.2 million from 4Kscore. Revenue in the comparable 2025 quarter had been $101.1 million, although the comparison was materially affected by the September 2025 oncology divestiture.

More significantly, revenue from retained operations declined approximately $1.7 million year over year. Management attributed much of this to changes in test mix, including the deliberate transfer of higher-priced but unprofitable esoteric testing to strategic partners.

That decision was economically rational. Revenue growth is not necessarily valuable when the incremental business loses money. However, it also illustrated the difficulty of expanding a laboratory business while simultaneously eliminating unattractive testing volume.

The reported operating results required careful interpretation.

BioReference's diagnostic segment recorded $4.8 million in operating income, compared with an $18.2 million operating loss in the prior-year quarter. On its face, this was a dramatic improvement.

But the reported result included an $18.1 million benefit from the final earnout payment associated with the 2025 oncology transaction. Removing that benefit produces an approximate operating loss of $13.3 million, before any other normalization.

This is not to dismiss the operating improvements. Expenses had declined substantially, and the company had eliminated significant fixed costs. But the accounting result did not establish that the continuing laboratory operation had achieved sustainable profitability.

Management also acknowledged higher employee-benefit and professional-fee expenses. The business remained exposed to cost pressures even after major workforce reductions.

The language of the July call continued to emphasize progress toward breakeven and sustainable profitability, rather than reporting that those goals had been attained.

StockAnalysis.com

Case interpretation: By July, BioReference's turnaround was incomplete. The company had materially reduced its cost structure, but recurring profitability remained elusive. Management nevertheless continued to present the business as an ongoing operation with future growth potential.

III. The Public Narrative: What Changed, and What Did Not?

Across the four calls, the remarkable feature is not a dramatic change in management's stated strategy. It is the persistence of essentially the same strategy despite increasingly mixed evidence about its results.

Evolution of management's public outlook

1. October 2025 — Strategic reset. The smaller laboratory would become more efficient and profitable.

2. February 2026 — Confidence. Management anticipated positive operating income and cash flow during 2026.

3. April 2026 — Evidence of progress. Volume and margins improved; breakeven was expected around midyear.

4. July 2026 — Unfinished execution. Operating profitability remained a goal, while the continuing business still showed losses after adjusting for a divestiture-related benefit.

5. October 2026 — Strategic exit. OPKO announced an agreement to sell the remaining laboratory enterprise.

There is no need to assume that management's earlier optimism was insincere. Operational improvement and divestiture can be complementary strategies. A buyer may pay more for a business that has reduced its costs, simplified its footprint, and stabilized its customer base.

Nevertheless, the public record raises a legitimate strategic question: Was OPKO primarily trying to establish BioReference as a sustainably profitable subsidiary, or was it improving the business to make it more attractive to a strategic acquirer?

The transcripts demonstrate the first objective clearly. They do not establish when the second objective became dominant.

The distinction matters because the economic justification for retaining BioReference inside OPKO was different from the justification for selling it to Labcorp.

For OPKO, BioReference required ongoing managerial attention, capital investment, and exposure to the economics of routine clinical testing. Its earnings potential had to be weighed against competing investments in pharmaceutical development and ModeX's biologics pipeline.

For Labcorp, the same business might be worth considerably more because of its existing laboratory infrastructure, purchasing power, distribution network, and ability to consolidate operations. Labcorp could also distribute 4Kscore through a national commercial network substantially larger than BioReference's.

Thus, the sale price need not imply that BioReference was on the verge of achieving the profitability OPKO had forecast. It could reflect the value of BioReference's assets in the hands of a more efficient owner.

IV. Sidebar: 4Kscore and the Long Search for a Prostate Diagnostics Blockbuster

4Kscore: An attractive clinical concept, but not yet a cash cow

The 4Kscore test has been central to OPKO's diagnostic strategy for more than a decade. Its clinical proposition is compelling: improve the assessment of clinically significant prostate cancer risk among men with abnormal PSA screening results, potentially reducing unnecessary prostate biopsies.

The test measures four kallikrein-related proteins—total PSA, free PSA, intact PSA, and human kallikrein-2—and combines these results with clinical information in a proprietary risk algorithm.

Unlike many emerging molecular diagnostics, 4Kscore has accumulated several important commercial advantages. These include clinical validation, incorporation into prostate cancer early-detection guidelines, an established CPT code (81539), Medicare and commercial reimbursement pathways, and FDA approval in 2021.

The 2025 FDA labeling expansion was especially promising. Eliminating the requirement for digital rectal examination information potentially made the test easier to order in primary care settings, broadening the addressable market beyond specialist urologists.

Yet the business has remained modest relative to its theoretical market potential.

In Q2 2026, 4Kscore contributed approximately $6.2 million in quarterly revenue, equivalent to an annualized run rate of about $25 million. That is meaningful for a specialized laboratory test, but hardly the scale of a diagnostic blockbuster.

The contrast between clinical promise and commercial results is striking. The prostate cancer screening population is enormous, and the test addresses a recognized clinical decision. Nevertheless, commercial expansion has been incremental, constrained by physician ordering habits, payer coverage, competition from other risk-stratification approaches, and the practical challenges of inserting a new diagnostic step into established care pathways.

The October 2026 transaction provides an unusually clear expression of 4Kscore's remaining perceived value. In addition to the $722 million base purchase price, Labcorp agreed to pay OPKO up to $150 million over as many as ten years, contingent on future 4Kscore revenue.

The contingent payment structure separates some of the test's future commercial upside from the immediate value of the acquired laboratory business. It is not evidence that 4Kscore is already generating blockbuster revenue; rather, it indicates that the parties see an opportunity for future growth whose realization remains uncertain.

Sources: OPKO's 2025 Form 10-K, Q2 2026 earnings call, and October 2026 transaction agreement.

OPKO Health, Inc. (OPK)

+2

A revealing comparison: ExoDx Prostate

The experience of another prostate cancer diagnostic illustrates the uncertainty of translating promising clinical technology into financial value.

Bio-Techne acquired Exosome Diagnostics in 2018 for approximately $250 million upfront, with the possibility of an additional $325 million in contingent payments. The acquisition included the ExoDx Prostate IntelliScore urine test, intended to help determine which men with elevated PSA levels should undergo prostate biopsy.

Bio-Techne presented the acquisition as an important expansion into liquid biopsy diagnostics. The transaction reflected considerable enthusiasm for exosome-based biomarkers and their potential applications across cancer diagnosis.

Seven years later, in September 2025, Bio-Techne sold the Exosome Diagnostics business to MDxHealth for total consideration of approximately $15 million.

The sale price was only about 6% of the original upfront acquisition consideration—a roughly 94% decline in nominal transaction value. The comparison is not a formal investment-return calculation, since the acquired and divested asset packages and intervening cash flows may differ. Nevertheless, it is a dramatic illustration of how commercial outcomes can diverge from initial expectations.

Bio-Techne Corporation

+2

The parallel with 4Kscore is instructive but not exact. Both products address prostate biopsy decisions. Both have attracted substantial corporate interest. Both have encountered the difficulty of turning clinical differentiation into widespread utilization and substantial profits.

Yet 4Kscore's inclusion in the Labcorp acquisition, together with its separate earnout arrangement, suggests continuing confidence in the test's commercial potential under a larger laboratory operator.

The broader lesson is that regulatory authorization, published clinical evidence, reimbursement, and even guideline recognition do not automatically create a highly profitable diagnostic franchise. Commercial scale must still be built.

V. The October 2026 Transaction: A Different Strategic Logic

On October 14, 2026, OPKO and Labcorp entered into an asset purchase agreement covering BioReference's remaining core laboratory businesses.

The financial terms were substantial: $722 million in cash at closing, subject to revenue-based adjustments, plus up to $150 million in future payments tied to 4Kscore revenue.

Labcorp expects approximately $250 million in revenue from the acquired operations during the first year after closing. That estimate is below the approximately $300 million annual revenue figure management discussed for the remaining BioReference operations in early 2026, although the figures are not necessarily comparable because of timing, scope, and operating changes.

Using Labcorp's $250 million estimate, the $722 million upfront consideration represents approximately 2.9 times expected first-year revenue. This is a simple transaction multiple, not an enterprise-value calculation adjusted for every transferred liability or asset. Still, it is a notable price for a laboratory business that had not demonstrated consistent operating profitability under its previous owner.

The buyer's strategic rationale is readily understandable. Labcorp would acquire an established regional laboratory presence, institutional customer relationships, correctional health testing operations, patient service centers, and a proprietary prostate cancer diagnostic with opportunities for broader national distribution.

OPKO's rationale was equally clear. Frost stated that the transaction would allow the company to streamline operations and focus resources on its biopharmaceutical business.

Labcorp

In retrospect, the three divestitures can be understood as a progressive transfer of BioReference's operations into a larger, more specialized laboratory enterprise, while OPKO redirected its corporate identity toward pharmaceutical and biologic development.

This interpretation does not establish that the final transaction was planned throughout the terminal year. It does, however, explain why a business publicly described as a promising turnaround candidate could ultimately be more valuable as an acquisition target than as a continuing subsidiary.

VI. Discussion: The Strategy Behind the Public Statements

The BioReference case presents several issues that are particularly relevant to healthcare executives, investors, and diagnostic entrepreneurs.

Operational improvement is not the same as strategic viability

BioReference's management had genuine operating achievements. The company reduced headcount, exited facilities, rationalized its test menu, and improved selected volume and margin measures.

But the July 2026 results showed that recurring operating profitability remained difficult to achieve. The business was smaller and more efficient, but still faced the structural disadvantages of competing with national-scale laboratories.

The distinction between making a business better and making it worth owning is central to the case.

The importance of adjusting reported earnings

The Q2 2026 results provide an unusually useful teaching example. A reported $4.8 million operating profit suggested that the turnaround might be succeeding. But an $18.1 million divestiture-related benefit more than accounted for that result.

An investor who failed to distinguish recurring operations from transaction-related accounting would reach a materially different conclusion about BioReference's performance.

The underlying business had improved, but the reported positive operating income was not proof of sustainable profitability.

The strategic value of scale

The final transaction also illustrates why the same assets can have different values in different corporate structures.

BioReference's laboratories, customer relationships, and specialized tests had value as a stand-alone operation. But Labcorp could potentially extract greater value through network integration, procurement efficiencies, laboratory consolidation, broader payer contracting, and national commercialization of proprietary tests.

The $722 million purchase price may therefore reflect expected synergies as much as BioReference's stand-alone earning power.

What did management know, and when?

The four earnings calls provide evidence of management's public statements, not a complete record of its internal deliberations.

The available material does not establish when OPKO began considering a final sale, when negotiations with Labcorp commenced, or whether the company was simultaneously pursuing both a turnaround and divestiture.

Those questions would require examination of subsequent SEC filings, transaction background disclosures, and potentially the sale agreement's supporting materials.

The more defensible conclusion is narrower and more interesting: throughout the terminal year, management publicly emphasized the future operating potential of BioReference, even as the company moved toward a transaction that would end OPKO's ownership of that business.

VII. Conclusion: A Turnaround That Ended in a Sale

BioReference's final year under OPKO was not characterized by an obvious public collapse or an announced retreat from clinical laboratory testing. Instead, it featured a consistent management narrative of restructuring, operational improvement, and anticipated profitability.

In October 2025, management presented the newly streamlined laboratory as a focused business with attractive growth opportunities. By February 2026, it expected positive operating income and cash flow during the year. In April, improved volume and margins appeared to support that confidence. By July, however, the continuing business had not yet demonstrated sustainable operating profitability, even though management remained committed publicly to the turnaround thesis.

Then came the October sale agreement.

The apparent contradiction is partly resolved by distinguishing operating strategy from corporate strategy. OPKO could reasonably seek to improve BioReference's operations while also recognizing that the business might be worth more to Labcorp than to OPKO shareholders as a continuing subsidiary.

Nevertheless, the retrospective is valuable precisely because the earnings calls preserve the company's public thinking before the final outcome was known.

They document the evolution of a business that management repeatedly characterized as approaching sustainable profitability, only to become the centerpiece of a major strategic divestiture.

The ultimate question is not simply whether BioReference could have become profitable. It is whether OPKO was ever the best owner of the business—and whether the increasingly concentrated American laboratory industry left much room for a third large independent competitor.

Primary Source Record

The case is based principally on four quarterly investor calls and OPKO's contemporaneous filings. These sources allow readers to distinguish management's contemporaneous expectations from the retrospective interpretation.

• OPKO earnings transcript archive — Q3 2025 and other quarterly calls.

• Q4 2025 earnings call, February 26, 2026.

• Q1 2026 earnings call, April 28, 2026.

• Q2 2026 earnings call, July 27, 2026.

• OPKO 2025 Form 10-K — restructuring history, 4Kscore commercialization, and operating strategy.

• October 2026 Form 8-K — transaction terms and closing conditions.

Case study prepared October 18, 2026. The October transaction is a signed agreement, not yet a completed sale. The case distinguishes reported financial results, management forecasts, and retrospective strategic interpretations.